Mavacamten prevails again, but the big question for Bristol is the commercial opportunity.
Lilly pips Pfizer to the big pharma top spot on share price performance, while Covid-19 drives the largest risers elsewhere.
A handful of huge success stories mask disappointing performances elsewhere, with small caps and Asian pharma firms feeling the pain.
Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
New findings for IL-6 blockade in the Recovery trial finally confirm a signal. Can pending pandemic readouts for other mechanisms do the same?
Myovant and Pfizer showed that deal-making was not taking a Christmas break, but for Celgene CVR holders the dream is almost over. And vaccine approvals gained pace.
It is vital that the first authorised at-home, non-prescription Covid-19 antigen test be used in the right way.